National Organization for Rare Disorders INC (Nord)

Based in DC

🤖

AI Overview

With $2.1M in lobbying spend across 38 quarterly filings, National Organization for Rare Disorders INC (Nord) is a significant lobbying presence. They deploy 17 individual lobbyists Their lobbying covers 7 issue areas. Active from 2018 to 2025.

$2.1M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$270K
2019	$320K
2020	$360K
2021	$360K
2022	$210K
2023	$140K
2024	$240K
2025	$250K

Issues Lobbied

Health Issues Medicare/Medicaid Pharmacy Budget/Appropriations Copyright/Patent Immigration Taxation

Lobbying Firms

National Organization for Rare Disorders, INC. (Nord)

Lobbyists

Paul Melmeyer Melanie Swick Buzzelli Peter Saltonstall Rachel Sher Rose Avellino Gallagher Timothy Boyd Michelle Adams Corinne Alberts Heidi Ross Richard White Ruby Dehkharghani Karin Hoelzer Allison Herrity Hayley Mason Mason Barrett Supraja Sowmiyanarayan Victoria Gemme

Government Agencies Targeted

These are the government entities that National Organization for Rare Disorders INC (Nord) disclosed contacting in their lobbying filings.

Centers For Medicare and Medicaid Services (CMS)Food & Drug Administration (FDA)Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESNatl Institutes of Health (NIH)SENATEOffice of Management & Budget (OMB)Bureau of Citizenship & Immigration Services (BCIS)Homeland Security, Dept of (DHS)Centers For Disease Control & Prevention (CDC)Social Security Administration (SSA)Natl Institute of Standards & Technology (NIST)

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Pharmacy, Budget/Appropriations, Copyright/Patent and 2 more

Bipartisan Health Care Stabilization Act

Medicare Part D

Right to Try Act; H.R.5247, S.204

Rare disease Advancement, Research, and Education Act of 2018; H.R.5115

National Institutes of Health Fundi

Medicare Part D

Right to Try Act; S.204

Rare disease Advancement, Research, and Education Act of 2018; H.R.5115

National Institutes of Health funding

Food and Drug Administration Appropriations

Orph

Medicare Part D

Step therapy in Medicare Advantage plans

Restoring the Patient's Voice Act of 2017; H.R.2077

Rare disease Advancement, Research, and Education Act of 2018; H.R.5115

National Institut

Medicare Part D

Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and develop

Medicare issues impacting patients with rare diseases.

Medicare Part D.